Search Videos by Topic or Participant
Browse by Series:

Therapeutic Options for Advanced Prostate Cancer

Panelists: Mark S. Austenfeld, MD, Kansas City Urology Care; Raoul S. Concepcion, MD, Urology Associates, PC; E. David Crawford, MD, University of Colorado;
Published: Tuesday, Sep 11, 2012
The addition of new therapeutic options for patients with advanced or metastatic prostate cancer has resulted in an increase in the number of patients being treated at a typical urology practice with advanced cancer.

Neal D. Shore, MD, provides details on the multiple therapies that are approved for patients with advanced prostate cancer. In general, androgen deprivation therapy (ADT) with leuprolide or GNRH antagonists remains a first-line therapy for patients who are still sensitive to androgen. For these patients, the antiresorptive agents denosumab and zoledronic acid can be used to help manage skeletal-related events (SREs).

Once patients show radiologic evidence of disease, the immunotherapy sipuleucel-T can be given in a 30 to 40-day completion with a very acceptable tolerability and safety profile, for asymptomatic castration-resistant prostate cancer (CRPC). Following progression, the cytotoxic agents docetaxel and cabazitaxel can be administered sequentially.

In the post chemotherapy space, two new oral agents have gained approval, abiraterone acetate and enzalutamide. The agent abiraterone acetate is an androgen biosynthesis inhibitor and lowers testosterone and testosterone metabolite levels by impacting the binding domain of the androgen receptor. The other agent, enzalutamide, directly binds to the androgen receptor and further prevents translocation at the level of the nucleus in the DNA. Shore believes that these agents both hold the potential to gain approval in the prechemotherapy setting.
Slider Left
Slider Right
The addition of new therapeutic options for patients with advanced or metastatic prostate cancer has resulted in an increase in the number of patients being treated at a typical urology practice with advanced cancer.

Neal D. Shore, MD, provides details on the multiple therapies that are approved for patients with advanced prostate cancer. In general, androgen deprivation therapy (ADT) with leuprolide or GNRH antagonists remains a first-line therapy for patients who are still sensitive to androgen. For these patients, the antiresorptive agents denosumab and zoledronic acid can be used to help manage skeletal-related events (SREs).

Once patients show radiologic evidence of disease, the immunotherapy sipuleucel-T can be given in a 30 to 40-day completion with a very acceptable tolerability and safety profile, for asymptomatic castration-resistant prostate cancer (CRPC). Following progression, the cytotoxic agents docetaxel and cabazitaxel can be administered sequentially.

In the post chemotherapy space, two new oral agents have gained approval, abiraterone acetate and enzalutamide. The agent abiraterone acetate is an androgen biosynthesis inhibitor and lowers testosterone and testosterone metabolite levels by impacting the binding domain of the androgen receptor. The other agent, enzalutamide, directly binds to the androgen receptor and further prevents translocation at the level of the nucleus in the DNA. Shore believes that these agents both hold the potential to gain approval in the prechemotherapy setting.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High CancersAug 29, 20182.0
Publication Bottom Border
Border Publication
x